<DOC>
	<DOCNO>NCT01076751</DOCNO>
	<brief_summary>Primary Objective : - Describe real-life survival CRPC patient receive first-line docetaxel disease progression Secondary Objective : - Describe treatment pattern - Describe characteristic outcomes patient receive second-line taxane-based treatment compare others - Describe economic patient-reported outcome</brief_summary>
	<brief_title>Observational Registry Treatment Patterns Castrate-resistant Prostate Cancer ( CRPC ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Patients CRPC progress course first line docetaxelbased chemotherapy least 3 cycle ( equivalent 225mg/m2 ) first line docetaxelbased chemotherapy Patient give write consent Exclusion criterion : Current participation clinical trial secondline treatment prostate cancer Patients receive less 3 cycle first line docetaxelbased chemotherapy discontinue reason disease progression toxicity Patients already start second line treatment The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>